Effect of Professional and Extra-Professional Exposure on Seroprevalence of SARS-CoV-2 Infection among Healthcare Workers of the French Alps: A Multicentric Cross-Sectional Study
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Context, Design, and Population
2.2. Serology Testing
2.3. Healthcare Worker Classification
2.4. Sample Size
2.5. Statistical Analysis
2.6. Patient and Public Involvement
3. Results
3.1. Characteristics of Respondents
3.2. Local Prevention Measures and Epidemiology in Each Hospital
3.3. Prevalence of SARS-CoV-2 Infection
3.4. Factors Associated with an Increased Prevalence
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Appendix A
- (1)
- What is your occupation (unique choice)?
- (2)
- Usual affectation (before COVID-19 period) (unique choice)?
- (3)
- Usual working time:
- Before COVID-19 pandemic (unique choice)?
- During COVID-19 pandemic (unique choice)?
- (4)
- Did you work remotely during lockdown (unique choice)?
- (5)
- During lockdown, did you work at least 12 h physically per day (unique choice)?
- (6)
- According to you, between February and May 2020, did you work longer than your usual working time?
- COVID-19 PREVENTION MESURES
- (7)
- Did you receive hygiene training since your recruitment?
- (8)
- Since February 2020, did you receive specific COVID-19 hygiene information?
- ○
- Surgical mask use
- ○
- Particle filter disposable system (FFP2) use
- ○
- Hands hygiene
- ○
- Professional scrubs
- ○
- Patient orientation
- ○
- Case definition and screening
- (9)
- Complete the following questions only if you have a patient-facing role:
- Are you aware of the WHO guidelines on hand hygiene in health care?
- (10)
- During the COVID-19 period, did you wear a surgical mask at work (unique choice)?
- (11)
- During the COVID-19 period, were you exposed to aerosol-generating procedures (nasopharyngeal test, intubation, etc.) for COVID-19 or non-COVID-19 patients?
- SYMPTOMS
- (12)
- During the past six months, have you had one or more symptoms?
- ○
- Fever
- ○
- Sore throat
- ○
- Cough
- ○
- Nasal discharge
- ○
- Dyspnea
- ○
- Chills
- ○
- Vomiting
- ○
- Nausea
- ○
- Diarrhea
- ○
- Headache
- ○
- Skin rash
- ○
- Conjunctivitis
- ○
- Muscle pain/aches
- ○
- Loss of appetite
- ○
- Loss of smell (anosmia) or taste
- ○
- Nose bleeds
- ○
- Tired
- ○
- Convulsions
- ○
- Altered consciousness
- ○
- Other neurological signs
- ○
- Other symptoms
- Please indicate the intensity of your symptoms from 0 (no symptoms) to 10 (most intense symptoms)
- (13)
- Have you ever performed a PCR test for SARS-CoV-2?
- RISK CONTACT AT WORK
- (14)
- In your professional activity during the past 6 months, have you had direct contact (s) with COVID-19 or non-COVID-19 patients within one meter (unique choice)?
- (15)
- Have you worked in a COVID-19 unit (unique choice)?:
- (16)
- Have you been in direct contact with a confirmed COVID-19 patient, without adequate protection (unique choice)?
- (17)
- Have there been any professional clusters of COVID-19 infection in your unit?
- (18)
- If your activity takes place in a non-COVID-19 unit, have there been any clusters of COVID-19 infection in patients/residents?
- (19)
- In your professional activity, have you complied with physical distancing when not wearing a facemask (i.e., during breaks) (unique choice):
- (20)
- During your professional activity, have you been in contact (without suitable protective measures) with a work colleague confirmed to have COVID-19 (unique choice)?
- EXTRA-PROFESSIONAL RISK CONTACT
- (21)
- At home, you live (unique choice):
- (22)
- In your household, there are children <18 years old (unique choice):
- (23)
- In your household, there are other caregivers than you:
- (24)
- In the past 6 months, have you been in contact (without adequate protection) with a confirmed case of COVID-19 in your family:
- (25)
- In the past 6 months, have you been in contact (without adequate protection) with a confirmed case of COVID-19 in extra-family private life:
- (26)
- In the past 6 months, have you used public transport (unique choice)?
- (27)
- In the past 6 months, have you been in contact with no protective measures with a sick person (respiratory symptoms, such as cough, dyspnea, fever)?
Appendix B
Characteristics and Timing of Reported Symptoms | Missing (%) | Overall | Negative Serology | Positive Serology | p-Value |
---|---|---|---|---|---|
N = 3454 | N = 3281 | N = 173 | |||
N (%) | N (%) | N (%) | |||
Reporting symptoms compatible with COVID-19 | 0.0% | 2254 (65.3) | 2098 (63.9) | 156 (90.2) | <0.001 |
Fever | 1.7% | 589 (17.3) | 508 (15.8) | 81 (47.1) | <0.001 |
Sore throat | 1.7% | 414 (12.2) | 364 (11.3) | 50 (29.1) | <0.001 |
Cough | 1.7% | 1037 (30.5) | 973 (30.2) | 64 (37.2) | 0.062 |
Nasal discharge | 1.7% | 963 (28.3) | 879 (27.3) | 84 (48.8) | <0.001 |
Dyspnea | 1.7% | 1155 (34.0) | 1074 (33.3) | 81 (47.1) | <0.001 |
Chills | 1.7% | 424 (12.5) | 371 (11.5) | 53 (30.8) | <0.001 |
Digestive symptoms | 1.7% | 692 (20.4) | 644 (20.0) | 48 (27.9) | 0.015 |
Vomiting | 1.7% | 111 (3.3) | 105 (3.3) | 6 (3.5) | 1.000 |
Nausea | 1.7% | 332 (9.8) | 310 (9.6) | 22 (12.8) | 0.216 |
Diarrhea | 1.7% | 513 (15.1) | 472 (14.6) | 41 (23.8) | 0.002 |
Headache | 1.7% | 1325 (39.0) | 1226 (38.0) | 99 (57.6) | <0.001 |
Skin rash | 1.7% | 114 (3.4) | 102 (3.2) | 12 (7.0) | 0.013 |
Conjunctivitis | 1.7% | 113 (3.3) | 106 (3.3) | 7 (4.1) | 0.734 |
Muscle pain/aches | 1.7% | 650 (19.1) | 575 (17.8) | 75 (43.6) | <0.001 |
Loss of appetite | 1.7% | 191 (5.6) | 155 (4.8) | 36 (20.9) | <0.001 |
Loss of smell (anosmia) or taste | 1.7% | 149 (4.4) | 77 (2.4) | 72 (41.9) | <0.001 |
Nose bleeds | 1.7% | 83 (2.4) | 74 (2.3) | 9 (5.2) | 0.029 |
Tired | 1.7% | 1379 (40.6) | 1269 (39.3) | 110 (64.0) | <0.001 |
Neurological signs | 1.7% | 36 (1.1) | 32 (1.0) | 4 (2.3) | 0.200 |
Convulsions | 1.7% | 10 (0.3) | 10 (0.3) | 0 (0.0) | 0.993 |
Altered consciousness | 1.7% | 7 (0.2) | 6 (0.2) | 1 (0.6) | 0.802 |
Other neurological signs | 1.7% | 19 (0.6) | 16 (0.5) | 3 (1.7) | 0.107 |
Other symptoms | 1.7% | 67 (2.0) | 58 (1.8) | 9 (5.2) | 0.004 |
Time between symptoms and serological screening | 34.8% | 0.014 | |||
≤14 days | 104 (4.6) | 102 (4.9) | 2 (1.3) | ||
15–29 days | 194 (8.6) | 188 (9.0) | 6 (3.8) | ||
≥30 days | 1857 (82.5) | 1714 (81.8) | 143 (91.7) | ||
Not disclosed | 96 (4.3) | 91 (4.3) | 5 (3.2) | ||
Performed RT-PCR for COVID-19 | 0.1% | 631 (18.3) | 544 (16.6) | 87 (50.6) | <0.001 |
Positive | 0.1% | 84 (2.4) | 19 (0.6) | 65 (37.8) | |
Negative | 547 (15.9) | 525 (16.0) | 22 (12.8) |
Appendix C
Hospital Characteristics | Hospital 1 | Hospital 2 | Hospital 3 | Hospital 4 |
---|---|---|---|---|
Before COVID-19 | ||||
Number of medical and surgical beds | 886 | 377 | 972 | 265 |
Number of ICU beds | 16 | 12 | 18 | 0 |
Local epidemiology (from 2 February 2020 to 30 June 2020) | ||||
Total of COVID-19 patients admitted to the hospital during the period | 533 | 262 | 275 | 249 |
Number of COVID-19 patients admitted to medical-surgical beds | 441 | 247 | 250 | 249 |
Date of peak | 1 April | 30 March | 31 March | 14 April |
At peak, occupation rate of COVID-19 cases † | 12.6% | 15.1% | 9.5% | 21.9% |
At peak, percentage increase in ICU beds | 268% | 275% | 211% | NA |
Mortality rate (all-cause) among COVID-19 patients | 9.7% | 6.5% | 14.9% | 9.6% |
Number of outbreaks in units (clusters) * | 3 | NA | 1 | 0 |
Nurse ratio in COVID-19 unit | 1 nurse/7 beds | NA | 1 nurse/10 beds | 1 nurse/10 beds |
Local anti-COVID-19 measures | ||||
Number of hygienists per 1000 medico-surgical beds | 2.48 | 1.06 | 2.73 | 1.9 |
COVID-19 patient’s hospitalization in dedicated units | Always | NA | Often | Always |
Date of systematic surgical mask-wearing recommendation for HCW with a patient-facing role | Before COVID-19 (flu) | March 26 | Before COVID-19(flu) | March 9 |
Date of systematic surgical mask-wearing recommendation for all HCW (including administrative staff) | 20 March | 26 March | 17 March | 9 March |
Systematic use of disposable filter respiratory protection (N95/FFP2) for all contacts with COVID-19 confirmed or suspected patients | Not systematic | Not systematic | Not systematic | Not systematic |
Modification of protective equipment recommendations due to shortage | For surgical masks only | For surgical masks only | No | No |
Appendix D
References
- Shah, A.S.V.; Wood, R.; Gribben, C.; Caldwell, D.; Bishop, J.; Weir, A.; Kennedy, S.; Reid, M.; Smith-Palmer, A.; Goldberg, D.; et al. Risk of hospital admission with coronavirus disease 2019 in healthcare workers and their households: Nationwide linkage cohort study. BMJ 2020, 371, m3582. [Google Scholar] [CrossRef]
- Martin, C.; Montesinos, I.; Dauby, N.; Gilles, C.; Dahma, H.; Van Den Wijngaert, S.; De Wit, S.; Delforge, M.; Clumeck, N.; Vandenberg, O. Dynamics of SARS-CoV-2 RT-PCR positivity and seroprevalence among high-risk healthcare workers and hospital staff. J. Hosp. Infect. 2020, 106, 102–106. [Google Scholar] [CrossRef] [PubMed]
- Solodky, M.L.; Galvez, C.; Russias, B.; Detourbet, P.; N’Guyen-Bonin, V.; Herr, A.-L.; Zrounba, P.; Blay, J.-Y. Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19. Ann. Oncol. 2020, 31, 1087–1088. [Google Scholar] [CrossRef] [PubMed]
- Guery, R.; Delaye, C.; Brule, N.; Nael, V.; Castain, L.; Raffi, F.; De Decker, L. Limited effectiveness of systematic screening by nasopharyngeal RT-PCR of medicalized nursing home staff after a first case of COVID-19 in a resident. Med. Mal. Infect. 2020, 50, 748–750. [Google Scholar] [CrossRef] [PubMed]
- Contejean, A.; Leporrier, J.; Canouï, E.; Alby-Laurent, F.; Lafont, E.; Beaudeau, L.; Parize, P.; Lecieux, F.; Greffet, A.; Chéron, G.; et al. Comparing dynamics and determinants of SARS-CoV-2 transmissions among health care workers of adult and pediatric settings in central Paris. Clin. Infect. Dis. 2020. [Google Scholar] [CrossRef]
- Self, W.H.; Tenforde, M.W.; Stubblefield, W.B.; Feldstein, L.R.; Steingrub, J.S.; Shapiro, N.I.; Ginde, A.A.; Prekker, M.E.; Brown, S.M.; Peltan, I.D.; et al. Seroprevalence of SARS-CoV-2 Among Frontline Health Care Personnel in a Multistate Hospital Network-13 Academic Medical Centers, April–June 2020. MMWR Morb. Mortal. Wkly. Rep. 2020, 69, 1221–1226. [Google Scholar] [CrossRef]
- Food and Drug Administration. EUA Authorized Serology Test Performance; FDA: Washingtown, DC, USA, 2021.
- International Standard Classifications of Occupations (ISCO-08). Available online: https://score.tools.who.int/tools/optimize-health-service-data/tool/international-standard-classifications-of-occupations-isco-08-45/ (accessed on 16 March 2021).
- Le Vu, S.; Jones, G.; Anna, F.; Rose, T.; Richard, J.-B.; Bernard-Stoecklin, S.; Goyard, S.; Demeret, C.; Helynck, O.; Escriou, N.; et al. Prevalence of SARS-CoV-2 antibodies in France: Results from nationwide serological surveillance. Nat. Commun. 2021, 12, 3025. [Google Scholar] [CrossRef]
- Jespersen, S.; Mikkelsen, S.; Greve, T.; Kaspersen, K.A.; Tolstrup, M.; Boldsen, J.K.; Redder, J.D.; Nielsen, K.; Abildgaard, A.M.; Kolstad, H.A.; et al. Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Survey Among 17 971 Healthcare and Administrative Personnel at Hospitals, Prehospital Services, and Specialist Practitioners in the Central Denmark Region. Clin. Infect. Dis. 2020. [Google Scholar] [CrossRef]
- Steensels, D.; Oris, E.; Coninx, L.; Nuyens, D.; Delforge, M.-L.; Vermeersch, P.; Heylen, L. Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a Tertiary Center in Belgium. JAMA 2020, 324, 195. [Google Scholar] [CrossRef]
- Plebani, M.; Padoan, A.; Fedeli, U.; Schievano, E.; Vecchiato, E.; Lippi, G.; Lo Cascio, G.; Porru, S.; Palù, G. SARS-CoV-2 serosurvey in health care workers of the Veneto Region. Clin. Chem. Lab. Med. (CCLM) 2020. [Google Scholar] [CrossRef]
- Lidström, A.-K.; Sund, F.; Albinsson, B.; Lindbäck, J.; Westman, G. Work at inpatient care units is associated with an increased risk of SARS-CoV-2 infection; a cross-sectional study of 8679 healthcare workers in Sweden. Ups. J. Med. Sci. 2020, 125, 305–310. [Google Scholar] [CrossRef] [PubMed]
- Eyre, D.W.; Lumley, S.F.; O’Donnell, D.; Campbell, M.; Sims, E.; Lawson, E.; Warren, F.; James, T.; Cox, S.; Howarth, A.; et al. Differential occupational risks to healthcare workers from SARS-CoV-2 observed during a prospective observational study. Elife 2020, 9. [Google Scholar] [CrossRef] [PubMed]
- Delmas, C.; Plu-Bureau, G.; Canouï, E.; Mouthon, L.; Meritet, J.-F. Clinical characteristics and persistence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) IgG antibodies in 4607 French healthcare workers: Comparison with European countries. Infect. Control Hosp. Epidemiol. 2020, 1–2. [Google Scholar] [CrossRef]
- Dimeglio, C.; Herin, F.; Miedougé, M.; Cambus, J.-P.; Abravanel, F.; Mansuy, J.-M.; Soulat, J.-M.; Izopet, J. Screening for SARS-CoV-2 antibodies among healthcare workers in a university hospital in southern France. J. Infect. 2021, 82, e29–e32. [Google Scholar] [CrossRef] [PubMed]
- Péré, H.; Wack, M.; Védie, B.; Demory Guinet, N.; Kassis Chikani, N.; Janot, L.; Bélec, L.; Veyer, D. Sequential SARS-CoV-2 IgG assays as confirmatory strategy to confirm equivocal results: Hospital-wide antibody screening in 3569 staff health care workers in Paris. J. Clin. Virol. 2020, 132, 104617. [Google Scholar] [CrossRef] [PubMed]
- Hausfater, P.; Boutolleau, D.; Lacombe, K.; Beurton, A.; Dumont, M.; Constantin, J.-M.; Ghosn, J.; Combes, A.; Cury, N.; Guedj, R.; et al. Cumulative incidence of SARS-CoV-2 infection and associated risk factors among frontline health care workers in Paris, France: The SEROCOV prospective cohort study. medRxiv 2021. [Google Scholar] [CrossRef]
- Shields, A.; Faustini, S.E.; Perez-Toledo, M.; Jossi, S.; Aldera, E.; Allen, J.D.; Al-Taei, S.; Backhouse, C.; Bosworth, A.; Dunbar, L.A.; et al. SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: A cross-sectional study. Thorax 2020, 75, 1089–1094. [Google Scholar] [CrossRef]
- Rudberg, A.-S.; Havervall, S.; Månberg, A.; Jernbom Falk, A.; Aguilera, K.; Ng, H.; Gabrielsson, L.; Salomonsson, A.-C.; Hanke, L.; Murrell, B.; et al. SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden. Nat. Commun. 2020, 11. [Google Scholar] [CrossRef]
- Sims, M.D.; Maine, G.N.; Childers, K.L.; Podolsky, R.H.; Voss, D.R.; Berkiw-Scenna, N.; Oh, J.; Heinrich, K.E.; Keil, H.; Kennedy, R.H.; et al. COVID-19 seropositivity and asymptomatic rates in healthcare workers are associated with job function and masking. Clin. Infect. Dis. 2020. [Google Scholar] [CrossRef]
- Piccoli, L.; Ferrari, P.; Piumatti, G.; Jovic, S.; Rodriguez, B.F.; Mele, F.; Giacchetto-Sasselli, I.; Terrot, T.; Silacci-Fregni, C.; Cameroni, E.; et al. Risk assessment and seroprevalence of SARS-CoV-2 infection in healthcare workers of COVID-19 and non-COVID-19 hospitals in Southern Switzerland. Lancet Reg. Health-Eur. 2021, 1, 100013. [Google Scholar] [CrossRef]
- Moscola, J.; Sembajwe, G.; Jarrett, M.; Farber, B.; Chang, T.; McGinn, T.; Davidson, K.W. Northwell Health COVID-19 Research Consortium Prevalence of SARS-CoV-2 Antibodies in Health Care Personnel in the New York City Area. JAMA 2020, 324, 893. [Google Scholar] [CrossRef]
- Olivier, C.; Brunet, J.; Bouvet, E.; Abiteboul, D.; Lolom, I.; Pellissier, G.; Delaroque-Astagneau, E.; Rouveix, E. Context of Healthcare Workers contamination during the first SARS-CoV-2 epidemic wave in France. Bull. Epidemiol. Hebd. 2020, 35, 690–695. [Google Scholar]
- Iversen, K.; Bundgaard, H.; Hasselbalch, R.B.; Kristensen, J.H.; Nielsen, P.B.; Pries-Heje, M.; Knudsen, A.D.; Christensen, C.E.; Fogh, K.; Norsk, J.B.; et al. Risk of COVID-19 in health-care workers in Denmark: An observational cohort study. Lancet Infect. Dis. 2020, 20, 1401–1408. [Google Scholar] [CrossRef]
- Post, N.; Eddy, D.; Huntley, C.; van Schalkwyk, M.C.I.; Shrotri, M.; Leeman, D.; Rigby, S.; Williams, S.V.; Bermingham, W.H.; Kellam, P.; et al. Antibody response to SARS-CoV-2 infection in humans: A systematic review. PLoS ONE 2020, 15, e0244126. [Google Scholar] [CrossRef] [PubMed]
Healthcare Worker Characteristics | Missing (%) | Overall | Hospital 1 | Hospital 2 | Hospital 3 | Hospital 4 |
---|---|---|---|---|---|---|
N = 3454 | N = 2016 | N = 823 | N = 172 | N = 443 | ||
Demographics | N (%) or Med (IQR) | N (%) or Med (IQR) | N (%) or Med (IQR) | N (%) or Med (IQR) | N (%) or Med (IQR) | |
Age, continuous (years) | 2.2% | 40.6 (31.8, 50.3) | 40.2 (31.8, 49.2) | 41.2 (32.0, 51.2) | 40.3 (32.6, 50.9) | 41.8 (31.3, 51.4) |
Sex, female | 0.0% | 2880 (83.4) | 1667 (82.7) | 683 (83.1) | 145 (84.3) | 385 (86.9) |
BMI, continuous (kg/m2) | 6.0% | 22.6 (20.4, 25.1) | 22.3 (20.3, 24.7) | 23.2 (20.8, 26.0) | 22.7 (20.8, 24.7) | 22.5 (20.2, 25.2) |
Children at home | 10.2% | 1695 (54.6) | 1031 (56.6) | 396 (53.7) | 80 (51.0) | 188 (48.3) |
Household, >1 inhabitant | 0.0% | 2078 (60.2) | 1232 (61.1) | 499 (60.6) | 100 (58.1) | 247 (55.8) |
Occupation according to ISCO † | 0.5% | |||||
Health management and support personnel | 854 (24.7) | 482 (23.9) | 225 (27.3) | 30 (17.4) | 117 (26.4) | |
Health associate professionals | 766 (22.2) | 442 (21.9) | 170 (20.7) | 49 (28.5) | 105 (23.7) | |
Health professionals | 1818 (52.6) | 1080 (53.6) | 425 (51.6) | 93 (54.1) | 220 (49.7) | |
Missing data | 16 (0.5) | 12 (0.6) | 3 (0.4) | 0 (0.0) | 1 (0.2) | |
Extra-professional exposure | ||||||
Intra-familial confirmed cases | 0.0% | 175 (5.1) | 96 (4.8) | 41 (5.0) | 11 (6.4) | 27 (6.1) |
Extra-familial confirmed cases | 0.1% | 185 (5.4) | 107 (5.3) | 39 (4.8) | 18 (10.5) | 21 (4.7) |
Professional exposure | ||||||
Working in emergency ward | 0.1% | 282 (8.2) | 151 (7.5) | 57 (6.9) | 0 (0.0) | 74 (16.7) |
Working in COVID-19 unit | 2.7% | |||||
Never | 1496 (44.5) | 885 (45.3) | 380 (47.4) | 81 (47.1) | 150 (34.6) | |
Sometimes | 749 (22.3) | 465 (23.8) | 175 (21.8) | 12 (7.0) | 97 (22.4) | |
Often | 382 (11.4) | 209 (10.7) | 90 (11.2) | 12 (7.0) | 71 (16.4) | |
Always | 734 (21.8) | 396 (20.3) | 156 (19.5) | 67 (39.0) | 115 (26.6) | |
Working in COVID-19 intensive care unit | 2.8% | 134 (4.0) | 71 (3.6) | 30 (3.8) | 27 (15.7) | 6 (1.4) |
Working in COVID-19 room | 2.8% | 1730 (51.5) | 999 (51.1) | 390 (48.8) | 64 (37.2) | 277 (64.0) |
Contact with COVID-19 patients without PPE ‡ | 3.9% | 866 (26.1) | 458 (23.9) | 200 (25.2) | 30 (17.4) | 178 (41.3) |
Cluster of cases among the team | 0.1% | 1102 (31.9) | 578 (28.7) | 245 (29.8) | 67 (39.0) | 212 (48.1) |
Cluster of cases among patients | 0.0% | 283 (8.2) | 188 (9.3) | 50 (6.1) | 6 (3.5) | 39 (8.8) |
Performed aerosol-generating tasks | 2.4% | 1033 (30.7) | 616 (31.5) | 221 (27.5) | 70 (41.2) | 126 (28.6) |
N95/FFP2 mask during aerosol generating-tasks | 2.6% | |||||
Not applicable | 2337 (69.5) | 1341 (68.6) | 582 (72.8) | 100 (58.8) | 314 (71.7) | |
Never | 82 (2.4) | 54 (2.8) | 21 (2.6) | 2 (1.2) | 5 (1.1) | |
Sometimes | 107 (3.2) | 59 (3.0) | 32 (4.0) | 2 (1.2) | 14 (3.2) | |
Often | 261 (7.8) | 158 (8.1) | 61 (7.6) | 11 (6.5) | 31 (7.1) | |
Always | 576 (17.1) | 343 (17.5) | 104 (13.0) | 55 (32.4) | 74 (16.9) | |
Systematic wear of surgical face mask | 0.0% | 2715 (78.6) | 1601 (79.4) | 612 (74.4) | 163 (94.8) | 339 (76.5) |
SARS-CoV-2 infection | ||||||
Seroprevalence of COVID-19 | 0.0% | 173 (5.0) | 66 (3.3) | 53 (6.4) | 8 (4.7) | 46 (10.4) |
Reporting symptoms compatible with COVID-19 | 0.0% | 2254 (65.3) | 1346 (66.8) | 493 (59.9) | 98 (57.0) | 317 (71.6) |
Time between symptoms and serological screening | 34.8% | |||||
≤14 days | 104 (4.6) | 61 (4.5) | 20 (4.1) | 13 (13.4) | 10 (3.2) | |
15–29 days | 194 (8.6) | 112 (8.3) | 36 (7.3) | 21 (21.6) | 25 (7.9) | |
≥30 days | 1857 (82.5) | 1102 (82.0) | 423 (85.8) | 62 (63.9) | 270 (85.2) | |
Not disclosed | 96 (4.3) | 69 (5.1) | 14 (2.8) | 1 (1.0) | 12 (3.8) | |
Performed RT-PCR for COVID-19 | 0.1% | 631 (18.3) | 263 (13.1) | 196 (23.8) | 77 (44.8) | 95 (21.4) |
Positive | 84 (13.3) | 35 (13.3) | 22 (11.2) | 14 (18.1) | 13 (13.7) | |
Negative | 547 (86.7) | 228 (86.7) | 174 (88.8) | 63 (81.8) | 82 (86.3) |
Variables | Univariate | Multivariate | ||||
---|---|---|---|---|---|---|
Odds Ratio | CI 95 | p-Value | Adjusted Odds Ratio | CI 95 | p-Value | |
Age (ref. 30 to 50 years) | ||||||
<30 years | 2.17 | (1.52–3.11) | <0.001 | 1.59 | (1.06–2.37) | 0.024 |
>50 years | 1.12 | (0.75–1.66) | 0.581 | 1.28 | (0.83–1.96) | 0.259 |
Female (ref. male) | 1.39 | (0.88–2.19) | 0.161 | 1.55 | (0.94–2.54) | 0.085 |
Profession, according to ISCO † (ref. health management and support personnel) | ||||||
Health associate professionals | 1.12 | (0.70–1.79) | 0.632 | 0.87 | (0.50–1.53) | 0.634 |
Health professionals | 1.27 | (0.86–1.87) | 0.223 | 0.67 | (0.39–1.16) | 0.157 |
Paramedical student or resident (ref. not a student) | 4.05 | (2.13–7.69) | <0.001 | 3.38 | (1.62–7.05) | 0.001 |
Patient-facing role (ref. not in facing role) | 1.61 | (1.09–2.38) | 0.016 | 1.10 | (0.65–1.87) | 0.712 |
Working in emergency ward (ref. not in emergency ward) | 1.51 | (0.93–2.44) | 0.097 | 0.85 | (0.49–1.49) | 0.571 |
Working in a COVID-19 unit (ref. not in COVID-19 unit) | 1.54 | (1.12–2.13) | 0.008 | 1.03 | (0.67–1.58) | 0.899 |
Contact with COVID-19 patients without PPE ‡ (ref. systematic use of PPE for contact with patients) | 2.37 | (1.73–3.25) | <0.001 | 1.66 | (1.12–2.44) | 0.011 |
Systematic wear of surgical face mask (ref. not systematic) | 0.93 | (0.65–1.34) | 0.706 | 0.71 | (0.45–1.13) | 0.151 |
Aerosol-generating task (ref. not concerned) | ||||||
Systematic use of FFP2 | 1.70 | (1.15–2.49) | 0.007 | 1.74 | (1.06–2.85) | 0.028 |
Without systematic use of FFP2 | 2.03 | (1.36–3.02) | <0.001 | 1.81 | (1.09–3.01) | 0.021 |
Cluster of cases among patients (ref. not) | 1.69 | (1.06–2.68) | 0.028 | 1.31 | (0.79–2.19) | 0.299 |
Cluster of cases within the team (ref. not) | 2.28 | (1.68–3.11) | <0.001 | 1.77 | (1.24–2.53) | 0.002 |
Working remotely at full-time (ref. not) | 1.41 | (0.51–3.95) | 0.509 | 2.39 | (0.79–7.19) | 0.121 |
Intra-familial confirmed cases (ref. not) | 2.47 | (1.49–4.09) | <0.001 | 2.09 | (1.15–3.80) | 0.015 |
Extra-familial confirmed cases (ref. not) | 1.47 | (0.82–2.64) | 0.199 | 0.81 | (0.40–1.64) | 0.555 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Vitrat, V.; Maillard, A.; Raybaud, A.; Wackenheim, C.; Chanzy, B.; Nguyen, S.; Valran, A.; Bosch, A.; Noret, M.; Delory, T. Effect of Professional and Extra-Professional Exposure on Seroprevalence of SARS-CoV-2 Infection among Healthcare Workers of the French Alps: A Multicentric Cross-Sectional Study. Vaccines 2021, 9, 824. https://doi.org/10.3390/vaccines9080824
Vitrat V, Maillard A, Raybaud A, Wackenheim C, Chanzy B, Nguyen S, Valran A, Bosch A, Noret M, Delory T. Effect of Professional and Extra-Professional Exposure on Seroprevalence of SARS-CoV-2 Infection among Healthcare Workers of the French Alps: A Multicentric Cross-Sectional Study. Vaccines. 2021; 9(8):824. https://doi.org/10.3390/vaccines9080824
Chicago/Turabian StyleVitrat, Virginie, Alexis Maillard, Alain Raybaud, Chloé Wackenheim, Bruno Chanzy, Sophie Nguyen, Amélie Valran, Alexie Bosch, Marion Noret, and Tristan Delory. 2021. "Effect of Professional and Extra-Professional Exposure on Seroprevalence of SARS-CoV-2 Infection among Healthcare Workers of the French Alps: A Multicentric Cross-Sectional Study" Vaccines 9, no. 8: 824. https://doi.org/10.3390/vaccines9080824
APA StyleVitrat, V., Maillard, A., Raybaud, A., Wackenheim, C., Chanzy, B., Nguyen, S., Valran, A., Bosch, A., Noret, M., & Delory, T. (2021). Effect of Professional and Extra-Professional Exposure on Seroprevalence of SARS-CoV-2 Infection among Healthcare Workers of the French Alps: A Multicentric Cross-Sectional Study. Vaccines, 9(8), 824. https://doi.org/10.3390/vaccines9080824